Molecular characterization of invasive serogroup Y Neisseria meningitidis strains isolated in the Latin America region

Abad, Raquel; Agudelo, Clara Inés; Brandileone, Maria Cristina C.; Chanto, Grettel; Gabastou, Jean Marc; Hormázabal, Juan Carlos; Gorla, Maria Cecília Outeiro; Maldonado, Aurora; Moreno, Jaime; Rouzic, Erwan Muros‐Le; Lersch, Robert A.; Regueira, Mabel; Salcedo, Celia; Sorhouet, Cecilia; Vázquez, Julio A.

doi:10.1016/j.jinf.2009.06.001

Cited by 27 publications

(21 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Higher GMTs in response to a third dose did not increase the percentage of subjects with hSBA titers ≥1:4 against NadA or fHbp, and it is unclear whether there is any clinical benefit of higher titers in response to the OMV component. Similar results were observed at 1 month after the 2-dose schedule both in the UK among 18-24 year old university students (99-100% achieved hSBA titers ≥1:4 against fHbp, NadA and PorA1.4) [47] and among [11][12][13][14][15][16][17] year old adolescents in Canada and Australia (99-100% achieved hSBA titers ≥1:5 against fHbp and NadA; 75% achieved hSBA titers ≥1:5 against PorA1.4) [43]. At two weeks after the second vaccination, 100% of subjects in the Canada and Australia study had hSBA titers ≥1:5 against strains fHbp and NadA; the percentage of subjects with hSBA ≥1:5 against strain NZ OMV at two weeks was higher compared to 1 month after vaccination (84-96%, 64-80%, respectively) [43].…”

Section: Responses To Various Vaccination Schedulessupporting

confidence: 74%

“…kissing, sharing drinks), smoking, and sleep deprivation [11][12][13]. While incidence peaks in adolescents are common in countries like the US, Canada, and Europe, some countries in Latin America do not exhibit such a prominent peak in its adolescent population [14][15][16][17]. This observation may be in part due to differences in college/university systems where, for example, dormitory housing is more common in the US but not in Chile.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Vaccination with a multicomponent meningococcal B vaccine in prevention of disease in adolescents and young adults

Nolan

O’Ryan

Wassil

et al. 2015

Vaccine

View full text Add to dashboard Cite

Vaccination programs employing capsular-based meningococcal vaccines have proved successful in a variety of settings globally since first introduced over 40 years ago. Similar successes have been demonstrated using meningococcal vaccines for use against serogroup B (MenB) outbreak strains but the diversity of MenB strains has limited vaccine use outside targeted geographic regions. MenB continues to be a significant cause of outbreaks in adolescents and young adults, as recently demonstrated in university settings in the US (Princeton, New Jersey and Santa Barbara, California) and has the potential for hyperendemic disease levels such as currently experienced in Québec and the United Kingdom. In adolescents, increased endemic disease rates and outbreak potential are likely associated with social behaviors putting individuals at risk for carriage acquisition and may explain regional and temporal variations in epidemiology. A protein-based, multi-component MenB vaccine (4CMenB) is currently licensed for use in 37 countries including EU/EEA countries, Australia, Canada, Chile, Colombia, Uruguay, and the US. In this article we review the most recent clinical trial data with 4CMenB with a focus on adolescents and young adults. The vaccine appears to have an acceptable safety profile and is well-tolerated in adolescents and young adults while providing robust, persistent levels of bactericidal antibodies considered protective for each of the four antigenic components of the vaccine. With the recent availability of this vaccine, health care providers have the first comprehensive opportunity to control meningococcal disease, a highly disruptive public health problem with a disproportionate impact on adolescents and young adults.

show abstract

Section: Responses To Various Vaccination Schedulessupporting

confidence: 74%

Section: Introductionmentioning

confidence: 99%

Vaccination with a multicomponent meningococcal B vaccine in prevention of disease in adolescents and young adults

Nolan

O’Ryan

Wassil

et al. 2015

Vaccine

View full text Add to dashboard Cite

show abstract

“…The lower frequency of serogroup Y and overall meningococcal carriage was reflected in a decrease in invasive meningococcal cases between 1998 and 2007 12. Serogroup Y disease has also been reported in South America, South Africa, Europe, and Israel 36,37. Most of the serogroup Y disease increase is associated with ST-23 and ST-167 clonal complexes 36,38.…”

Section: Changing Global Epidemiologymentioning

confidence: 94%

Meningococcal disease: changes in epidemiology and prevention

Chang¹,

Tzeng²,

Stephens³

2012

CLEP

View full text Add to dashboard Cite

The human bacterial pathogen Neisseria meningitidis remains a serious worldwide health threat, but progress is being made toward the control of meningococcal infections. This review summarizes current knowledge of the global epidemiology and the pathophysiology of meningococcal disease, as well as recent advances in prevention by new vaccines. Meningococcal disease patterns and incidence can vary dramatically, both geographically and over time in populations, influenced by differences in invasive meningococcal capsular serogroups and specific genotypes designated as ST clonal complexes. Serogroup A (ST-5, ST-7), B (ST-41/44, ST-32, ST-18, ST-269, ST-8, ST-35), C (ST-11), Y (ST-23, ST-167), W-135 (ST-11) and X (ST-181) meningococci currently cause almost all invasive disease. Serogroups B, C, and Y are responsible for the majority of cases in Europe, the Americas, and Oceania; serogroup A has been associated with the highest incidence (up to 1000 per 100,000 cases) and large outbreaks of meningococcal disease in sub-Saharan Africa and previously Asia; and serogroups W-135 and X have emerged to cause major disease outbreaks in sub-Saharan Africa. Significant declines in meningococcal disease have occurred in the last decade in many developed countries. In part, the decline is related to the introduction of new meningococcal vaccines. Serogroup C polysaccharide-protein conjugate vaccines were introduced over a decade ago, first in the UK in a mass vaccination campaign, and are now widely used; multivalent meningococcal conjugate vaccines containing serogroups A, C, W-135, and/or Y were first used for adolescents in the US in 2005 and have now expanded indications for infants and young children, and a new serogroup A conjugate vaccine has recently been introduced in sub-Saharan Africa. The effectiveness of these conjugate vaccines has been enhanced by the prevention of person-to-person transmission and herd immunity. In addition, progress has been made in serogroup B-specific vaccines based on conserved proteins and outer membrane vesicles. However, continued global surveillance is essential in understanding and predicting the dynamic changes in the epidemiology and biological basis of meningococcal disease and to influence the recommendations for current and future vaccines or other prevention strategies.

show abstract

“…The genotype was defined as 3-100:P1. (8)(9)(10)(11), suggesting that a common strain circulating in South America underwent a mutational event that led to the expression of the mixed polysaccharides described here. The monitoring of such isolates has implications for routine meningococcal disease surveillance.…”

mentioning

confidence: 85%

Invasive Neisseria meningitidis Strain Expressing Capsular Polysaccharides W and Y in Brazil

Barroso¹,

Castiñeiras²,

Rebelo³

et al. 2013

J Clin Microbiol

View full text Add to dashboard Cite

Molecular characterization of invasive serogroup Y Neisseria meningitidis strains isolated in the Latin America region

Cited by 27 publications

References 14 publications

Vaccination with a multicomponent meningococcal B vaccine in prevention of disease in adolescents and young adults

Vaccination with a multicomponent meningococcal B vaccine in prevention of disease in adolescents and young adults

Meningococcal disease: changes in epidemiology and prevention

Invasive Neisseria meningitidis Strain Expressing Capsular Polysaccharides W and Y in Brazil

Contact Info

Product

Resources

About